


Catalog # 10-4564

NLG919

CAS# 1402836-58-1

1-Cyclohexyl-2-(5H-imidazo[5,1-a]isoindol-5-yl)ethanol

Lot # FBS2001



NLG919 (1402836-58-1) is a potent IDO-pathway inhibitor ($K_i = 7\text{nM}$; $EC_{50} = 75\text{nM}$).¹ It synergizes with chemo-radiation therapy to promote T cell dependent complement deposition in a murine model of glioblastoma.² In combination with paclitaxel in a mouse B16-F10 melanoma model, NLG919 increased the percentage of CD3⁺, CD8⁺, and CD4⁺ T cells and secretion of IFN- γ and interleukin-2 while decreasing the percentage of CD4⁺CD25⁺ regulatory T cells.³

- 1) Mautino *et al.* (2013), *NLG919, a novel indolamine-2,3-dioxygenase (IDO)-pathway inhibitor drug candidate for cancer therapy*; *Cancer Res.* **73** issue 8 supplement 491
- 2)) Li *et al.* (2014), *The indolamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma*; *J. Immunother. Cancer* **2** 21
- 3) Meng *et al.* (2017), *Combinatorial antitumor effects of indoleamine 2,3-dioxygenase inhibitor NLG919 and paclitaxel in a murine B16-F10 melanoma model*; *Int. J. Immunopathol. Pharmacol.* **30** 215

PHYSICAL DATA

Molecular Weight:	282.39
Molecular Formula:	C ₁₈ H ₂₂ N ₂ O
Purity:	>98% by HPLC
	NMR: (Conforms)
Solubility:	DMSO (15 mg/ml)
Physical Description:	White solid
Storage and Stability:	Store as supplied at -20°C for up to 1 year from the date of purchase. Solutions in DMSO may be stored at -20°C for up to 1 month.

Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications.